Open Access Gold möglich sobald Verlagsversion bei der ZB eingereicht worden ist.
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.
J. Immunother. 36, 133-151 (2013)
Nine cancer patients were treated with adoptive cell therapy using autologous anti-MAGE-A3 T-cell receptors (TCR)engineered T cells. Five patients experienced clinical regression of their cancers including 2 on-going responders. Beginning 1-2 days postinfusion, 3 patients (#'s 5, 7, and 8) experienced mental status changes, and 2 patients (5 and 8) lapsed into comas and subsequently died. Magnetic resonance imagining analysis of patients 5 and 8 demonstrated periventricular leukomalacia, and examination of their brains at autopsy revealed necrotizing leukoence-phalopathy with extensive white matter defects associated with infiltration of CD3(+) /CD8(+) T cells. Patient 7, developed Parkinson- like symptoms, which resolved over 4 weeks and fully recovered. Immunohistochemical staining of patient and normal brain samples demonstrated rare positively staining neurons with an antibody that recognizes multiple MAGE-A family members. The TCR used in this study recognized epitopes in MAGE-A3/A9/A12. Molecular assays of human brain samples using real-time quantitative-polymerase chain reaction, Nanostring quantitation, and deep-sequencing indicated that MAGE-A12 was expressed in human brain (and possibly MAGE-A1, MAGE-A8, and MAGEA9). This previously unrecognized expression of MAGE-A12 in human brain was possibly the initiating event of a TCR-mediated inflammatory response that resulted in neuronal cell destruction and raises caution for clinical applications targeting MAGE-A family members with highly active immunotherapies.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Cancer-testes Antigen ; Immunotherapy ; Tcr ; Gene Therapy; Inflammatory Demyelinating Polyneuropathy ; Adoptive Cell Therapy ; Cd8(+) T-cells ; Mage-a Family ; Metastatic Melanoma ; Multiple-sclerosis ; Cancer/testis Antigens ; Malignant-melanoma ; Prostate-cancer ; Clinical-trial
ISSN (print) / ISBN
1524-9557
e-ISSN
1537-4513
Zeitschrift
Journal of Immunotherapy
Quellenangaben
Band: 36,
Heft: 2,
Seiten: 133-151
Verlag
Lippincott Williams & Wilkins
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Molecular Immunology (IMI)